1. Core Mechanism of LDN

• Low Dose Naltrexone (LDN) temporarily blocks opioid receptors
• This creates a transient drop in endorphins
• The body typically responds by:
  • Increasing endogenous endorphin production
  • Leading to a rebound effect

2. Endorphin Deficiency Phenomenon

• Not all patients compensate effectively
• Some develop functional endorphin deficiency

Clinical Presentation

• Mild → severe nausea
• Retching / GI discomfort
• Headaches
• Malaise (“feels unwell”)
• Fatigue / low energy
• Depressed or “gray” mood
• Poor or non-restorative sleep

3. Two Types of Symptoms on LDN

A. Expected (Transient) Effects

• Occur shortly after dosing
• Resolve within ~4 hours (drug half-life)
• Reflect temporary receptor blockade

B. Pathologic Endorphin Deficiency

• Symptoms persist or worsen over time
• Do NOT improve with continued dosing
• Indicates inadequate physiologic compensation

4. High-Risk Patients for Deficiency

Patients more likely to struggle:

• Already fatigued or burned out
• Poor sleepers (non-restorative sleep)
• Low baseline energy
• Chronic illness burden
• Possible neuroendocrine dysfunction

5. Clinical Assessment Framework

Three key questions to guide dosing:

• How much does the condition affect you? (1–10)
• How much does it reduce enjoyment of life?
• How much does it limit daily function?

6. Dosing Principles (Critical Insight)

Golden Rule:

Start low, go slow, individualize

• There is NO universal dose
• Sensitivity varies widely

Observed Reality

• Some tolerate standard doses (1.5–4.5 mg)
• Others react to:
  • 0.5 mg
  • 0.05 mg
  • Even microgram doses

7. Common Clinical Mistake

• Patients told to “push through” side effects
• This can worsen:
  • Endorphin depletion
  • Symptom burden

Correct Approach

• Worsening symptoms = signal to adjust dose
• Not a sign to persist blindly

8. Symptom-Guided Dosing

Dose should be adjusted based on:

• Sleep quality
• Energy levels
• Mood changes
• Functional capacity

→ Goal: Find the “sweet spot”

9. Key Concept: Sweet Spot

• Optimal dose = balance between:
  • Therapeutic benefit
  • Minimal side effects
• Highly individualized
• Requires iterative titration

10. Time Course Insight

• LDN half-life ≈ 4 hours
• Short-lived symptoms = expected
• Persistent symptoms = problem

11. Clinical Strategy

• Begin at the lowest tolerable dose
• Increase gradually
• Monitor closely for:
  • Worsening fatigue
  • Mood decline
  • Sleep disruption

12. Practical Takeaways

• LDN is not a simple protocol drug
• It is a precision, patient-specific therapy
• Success depends on:
  • Careful titration
  • Symptom interpretation
  • Avoiding rigid dosing protocols

Bottom Line

LDN works by temporarily lowering endorphins to trigger a rebound increase, but in vulnerable patients, this can instead lead to endorphin deficiency and worsening symptoms—making individualized dosing essential.